# Luis Alvarez

> Luis Alvarez is the founder and CEO of Theradaptive, a Frederick, Maryland biotech engineering proteins that latch onto implants and surgical materials to trigger the body to regrow bone, cartilage, and other tissue exactly where it is needed. A retired U.S. Army lieutenant colonel and MIT-trained biological engineer, he traced the idea back to a combat tour in Iraq, where soldiers under his command lost limbs to delayed amputations. Theradaptive has since won multiple FDA Breakthrough Device Designations, raised more than $43 million, and moved its lead protein, AMP2, into human clinical trials.

- **Role:** Founder & CEO at Theradaptive
- **Organizations:** Theradaptive, U.S. Army, U.S. Military Academy (West Point), Massachusetts Institute of Technology, Department of Defense Regenerative Medicine Program, DARPA, Federation of American Scientists, Hertz Foundation
- **Nationality:** American
- **Education:** B.S., Chemistry and Life Sciences, U.S. Military Academy at West Point, M.S., Chemical Engineering (Hertz Fellow), Massachusetts Institute of Technology, Ph.D., Biological Engineering (Hertz Fellow); thesis: Modulating Cell Behavior with Engineered HER-Receptor Ligands, Massachusetts Institute of Technology
- **Known for:** Founded and leads Theradaptive, a clinical-stage regenerative medicine company, Invented AMP2, a material-binding bone-inducing protein variant enabling targeted tissue regeneration, Secured multiple FDA Breakthrough Device Designations

## Career timeline

- **1997** — Graduates West Point as a chemistry and life sciences major and commissions into the U.S. Army
- **1999-2005** — Serves as an intelligence officer with deployments including Iraq and Korea
- **2006** — Returns to MIT for a PhD, driven by battlefield injuries he witnessed
- **2010s** — Academy Professor at West Point; DARPA Service Chief Fellow
- **2010s** — Co-founding Deputy Director of the DoD Regenerative Medicine Program; leads a ~$720M nerve-agent countermeasures program and the DoD's largest recombinant biologics effort through Phase II
- **2017** — Founds Theradaptive to commercialize targeted tissue regeneration
- **2023** — Closes a $26M Series A and wins a $7.4M DoD Clinical Trial Award for AMP2 Phase I/II studies
- **2024-2026** — Advances OsteoAdapt/AMP2 through clinical trials; secures Series B financing (total funding ~$43.4M)

## Achievements

- Founded and leads Theradaptive, a clinical-stage regenerative medicine company
- Invented AMP2, a material-binding bone-inducing protein variant enabling targeted tissue regeneration
- Secured multiple FDA Breakthrough Device Designations
- Retired U.S. Army lieutenant colonel with 20 years of service and a combat tour in Iraq
- 1997 Hertz Foundation Fellow; PhD in Biological Engineering from MIT
- Co-founded and served as Deputy Director of the DoD Regenerative Medicine Program
- Led a roughly $720M nerve-agent pharmaceutical countermeasures program
- Raised more than $43 million to advance the platform toward the clinic

## Latest updates

- **2023-01** — Closed a $26M Series A to advance the AMP2 platform
- **2023-01** — Won a $7.4M DoD Clinical Trial Award for AMP2 Phase I/II studies
- **2026-01** — Reported Series B stage financing; total funding reaches roughly $43.4M

## Links

- Website: https://theradaptive.com
- LinkedIn: http://www.linkedin.com/in/luisthx
- Twitter/X: https://twitter.com/theradaptive

---

Profile page: https://yespress.io/luis-alvarez
Published by YesPress — https://yespress.io
Last updated: 2026-07-01